A Simulation Platform to Examine Heterogeneity Influence on Treatment
Crawford, Matthew A.
Content, Charles F.
MetadataShow full item record
CitationChi, Chih-Lin, Vincent A. Fusaro, Prasad Patil, Matthew A. Crawford, Charles F. Content, and Peter J. Tonellato. 2012. A simulation platform to examine heterogeneity influence on treatment. AMIA Summits on Translational Science Proceedings 2012: 19-24.
AbstractAlthough a protocol aims to guide treatment management and optimize overall outcomes, the benefits and harms for each individual vary due to heterogeneity. Some protocols integrate clinical and genetic variation to provide treatment recommendation; it is not clear whether such integration is sufficient. If not, treatment outcomes may be sub-optimal for certain patient sub-populations. Unfortunately, running a clinical trial to examine such outcome responses is cost prohibitive and requires a significant amount of time to conduct the study. We propose a simulation approach to discover this knowledge from electronic medical records; a rapid method to reach this goal. We use the well-known drug warfarin as an example to examine whether patient characteristics, including race and the genes CYP2C9 and VKORC1, have been fully integrated into dosing protocols. The two genes mentioned above have been shown to be important in patient response to warfarin.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:10456092
- HMS Scholarly Articles